Top Stories
BioMarin is combining Profluent's de novo protein design approach with its enzyme therapy expertise to identify potential candidates more efficiently.
The company said one model predicted how an Alzheimer’s-linked protein changes in response to drugs, while the other outperformed rival systems on an external benchmark.
Novartis is working with CAS, a division of the American Chemical Society, while AbbVie has teamed up with Valkai for custom AI tools.
The initiative's first pilot will focus on heart failure, aiming to detect deterioration before symptoms emerge or hospitalisation occurs.
Ortet is focused on improving personalised healthcare.
Conference News
Analysis of 3,918 adults across Germany, the Netherlands and France, with no eligibility criteria beyond active system use, covering 323,814 person-days of real-world experienceUsers achieved median t...
Clinical documentation Improvement, medical coding, and revenue cycle expertise to help healthcare organizations improve accuracy and optimize financial performance.HERNDON, Va.--(BUSINESS WIRE)--ECLA...
CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (NASDAQ: TEM) today announced that 13 abstracts have been accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2026, taking...
AMRA Chief Scientific Officer Dr. Jennifer Linge will present at EASD 2026, highlighting how quantitative MRI can reveal changes in muscle that conventional measures does not fully capture.LINKÖPING, ...
Data show patients with low-risk DecisionDx-Melanoma i31-SLNB results had sentinel lymph node (SLN) positivity below 5% when biopsied, and eligible patients who avoided SLNB had five-year recurrence-f...
